Ceriotti Laura, Balzaretti Silvia, Barone Salvatore, Meloni Marisa
VitroScreen, Milan, Italy.
NTC S.r.l., Milan, Italy.
Clin Ophthalmol. 2020 Jan 24;14:257-267. doi: 10.2147/OPTH.S229879. eCollection 2020.
To assess the eye tolerability of a buffered ophthalmic solution containing microglycine (sodium hydroxymethylglycinate, mwater) in an in vitro model.
A multiple endpoint analysis (MEA) approach was applied to the reconstructed human corneal epithelium (HCE) model. Sodium hydroxymethylglycinate solution (0.04%) and two ophthalmic ointments containing microglycine (Protectorial, containing 0.02% of sodium hydroxymethylglycinate, and Edenight, containing 0.04% of sodium hydroxymethylglycinate) were investigated. The buffered solution and the ointments were tested on HCE after acute (one application in 24 hrs, followed or not by 16 hrs of recovery) or repeated (one application per day for three consecutive days) exposures; benzalkonium chloride (BAK) 0.01% and saline isotonic solution were used as positive and negative controls, respectively. Cellular viability, trans-epithelial electrical resistance (TEER), lactate dehydrogenase (LDH) release and histo-morphology were evaluated.
BAK 0.01% toxicity in HCE was confirmed for the 24+16 hrs acute and repeated exposure protocols, while, after 24-hours acute treatment, only modifications of the superficial cell layer were visible compared with the negative control. Sodium hydroxymethylglycinate had a very good tolerability profile and a neutral impact on the corneal surface after acute or repeated exposure. The Protectorial and Edenight ointments preserved cell viability in the different exposure protocols, suggesting a good local tolerability profile. Modifications of the superficial layers were observed on histo-morphological analysis and confirmed by increased release of LDH after 24+16 hrs acute exposure (+65% and +76% for Protectorial and Edenight, respectively) and TEER values after 24+16 hrs and 72 hrs exposure protocols. These results were dependent on the ointments' accumulation on the corneal epithelium due to their physical form (semi-solid) and lipophilic properties.
Sodium hydroxymethylglycinate, alone or as part of eye ointments, was found to be non-toxic after acute or repeated exposure in the reconstructed HCE model.
在体外模型中评估含有微甘氨酸(羟甲基甘氨酸钠,mwater)的缓冲眼用溶液的眼部耐受性。
将多终点分析(MEA)方法应用于重建的人角膜上皮(HCE)模型。研究了羟甲基甘氨酸钠溶液(0.04%)和两种含有微甘氨酸的眼药膏(Protectorial,含0.02%羟甲基甘氨酸钠;Edenight,含0.04%羟甲基甘氨酸钠)。在急性(24小时内单次给药,随后恢复16小时与否)或重复(连续三天每天单次给药)暴露后,在HCE上测试缓冲溶液和药膏;分别使用0.01%苯扎氯铵(BAK)和生理盐水等渗溶液作为阳性和阴性对照。评估细胞活力、跨上皮电阻(TEER)、乳酸脱氢酶(LDH)释放和组织形态学。
对于24 + 16小时急性和重复暴露方案,证实了0.01% BAK对HCE的毒性,而在24小时急性治疗后,与阴性对照相比,仅可见表层细胞层的改变。羟甲基甘氨酸钠具有非常好的耐受性,在急性或重复暴露后对角膜表面具有中性影响。Protectorial和Edenight药膏在不同暴露方案中保持细胞活力,表明局部耐受性良好。在组织形态学分析中观察到表层的改变,并通过24 + 16小时急性暴露后LDH释放增加(Protectorial和Edenight分别增加65%和76%)以及24 + 16小时和72小时暴露方案后的TEER值得到证实。这些结果取决于药膏因其物理形态(半固体)和亲脂性在角膜上皮上的积聚。
在重建的HCE模型中,发现羟甲基甘氨酸钠单独或作为眼药膏的一部分,在急性或重复暴露后无毒。